Welcome to our dedicated page for TC BioPharm (Holdings) news (Ticker: TCBP), a resource for investors and traders seeking the latest updates and insights on TC BioPharm (Holdings) stock.
TC BioPharm (Holdings) PLC (TCBP) generates a steady flow of news as a clinical-stage biopharmaceutical company developing allogeneic gamma-delta T cell therapies for cancer and other indications. News coverage on this page focuses on the company’s clinical progress, strategic initiatives, and capital markets developments, helping readers follow how its gamma-delta T cell platform is advancing from early-stage research into later-stage trials and potential new indications.
Many updates relate to TCB008, the company’s lead gamma-delta T cell therapy candidate. Articles highlight milestones in the ACHIEVE Phase II UK clinical trial, including completion of dosing in Cohort A for relapsed or refractory acute myeloid leukemia patients, initial dosing and follow-up in Cohort B minimal residual disease patients, safety findings with no reported drug-related adverse events, and efficacy signals such as stable disease and complete molecular remission in at least one MRD patient. These reports provide insight into how TCB008 is performing in challenging hematologic malignancies.
Other news items cover strategic and corporate actions, such as TC BioPharm’s intention to conduct proof-of-concept preclinical studies of TCB008 in H5N1 (avian “bird flu”), a non-binding letter of intent to acquire a commercial-stage ophthalmic pharmaceutical company with an FDA-approved glaucoma treatment, and operational changes including a shift toward a CDMO-based manufacturing model and associated workforce reductions. Capital markets announcements, including an ADS ratio change and the company’s transition from Nasdaq to trading on OTC Markets, are also reported.
Investors and observers can use this news feed to track clinical data readouts, expansion into new therapeutic areas, proposed M&A activity, and listing or ADS structure changes. For those following TCBP, revisiting this page offers a consolidated view of how the company’s gamma-delta T cell programs and broader strategy evolve over time.
TC Biopharm (NASDAQ: TCBP) has been recognized by Kuick Research as a leading player in the gamma-delta T cell therapy market, projected to exceed $4 billion by 2028. The company is advancing its allogeneic gamma-delta T cell therapies, specifically with its OmnImmune® product, currently in a Phase 2b/3 trial for acute myeloid leukemia. Early trials showed a significant decrease in cancer levels from 38% to 6% without serious side effects. TC Biopharm’s operations and management position it well for growth in this promising sector.
TC Biopharm (NASDAQ: TCBP) announced the formation of a Scientific Advisory Board (SAB) to advance its gamma-delta T cell therapy, OmnImmune®, for Acute Myeloid Leukemia (AML). Dr. Mark Bonyhadi, with over 30 years in biopharmaceuticals, will lead the SAB alongside notable experts like Uma Lakshmipathy and Erin Adams. The SAB aims to bolster the company's research and development efforts in oncology. TC BioPharm is a leader in gamma-delta T cell therapies with ongoing phase II/III trials, demonstrating a commitment to innovation in the field of cancer treatment.
TC Biopharm (NASDAQ: TCBP), a clinical-stage biotechnology company, will present at the LD Micro Invitational from June 7th to 9th, 2022, at Four Seasons Westlake Village. This prestigious 3-day investor event will feature around 200 companies, each presenting for 25 minutes followed by private meetings. TC Biopharm specializes in gamma-delta T cell therapies for cancer and viral infections, leading the way in clinical studies. Currently, the company is conducting pivotal trials for its OmnImmune® product in acute myeloid leukemia and ImmuniStim for Covid-19 treatment.
TC Biopharm (NASDAQ: TCBP) announced its participation in multiple upcoming conferences focused on allogeneic gamma-delta T cell therapies for cancer. Michael Leek, Co-founder and Executive Chairman, will present at the Allogeneic Cell Therapies Summit in Boston from May 9-11, and the Advanced Therapies Conference in London on May 24-25. Additionally, he will speak at the Next Generation CAR & T Cell Therapies 2022 in San Francisco from June 14-16, and the Onco Cell Therapy Summit in Boston from June 29-30. These events showcase TC Biopharm's innovative approaches in clinical-stage biopharmaceuticals.
On April 21, 2022, TC Biopharm (NASDAQ: TCBP) announced a donation to the Leukemia and Lymphoma Society to raise awareness for World AML Day. As a clinical-stage biotechnology company, TC Biopharm is developing gamma-delta T cell therapies for cancer and viral conditions, with ongoing phase 2b/3 trials for its OmnImmune® treatment targeting acute myeloid leukemia (AML). CEO Bryan Kobel emphasized the company's commitment to advancing novel cell therapies while collaborating with healthcare institutions.
TC BioPharm (NASDAQ: TCBP) has achieved a significant milestone by successfully registering the trademark 'CryoTC®', a proprietary freeze-thaw process for its lead oncology product, OmnImmune®. This innovative process enhances the product's accessibility and storage, establishing it as an 'off the shelf' cell therapy for potential treatments of acute myeloid leukemia and other cancers. With a strong clinical pipeline, TC BioPharm aims to lead in gamma-delta T cell therapies, combining innate and adaptive immune responses to tackle various cancers and viral infections.
TC Biopharm (NASDAQ: TCBP) has received equity research coverage from EF Hutton, which issued a 'Buy' rating with a target price of $5. This rating follows TC Biopharm's key milestones, including successful Phase 1b/2a trial results in late-stage Acute Myeloid Leukemia (AML) patients treated with allogeneic gamma-delta T cells and the granting of orphan drug status for its product OmnImmune® in AML. The company focuses on developing gamma-delta T cell therapies for cancer and has a robust pipeline and significant intellectual property portfolio.
TC Biopharm announced that it has received MHRA and Research Ethics Committee approvals to begin clinical trials for its OmnImmune® therapy to treat Acute Myeloid Leukemia (AML). The Phase 2/3 trials are set to start enrollment in the first half of 2022 in the UK, with plans to expand into the US afterward. Previously, OmnImmune® received orphan drug designation from the FDA. CEO Bryan Kobel expressed enthusiasm about progressing with their proprietary therapy following promising Phase 1b/2a results. The company is focused on developing gamma-delta T cell therapies with a strong pipeline for future indications.
On March 17, 2022, TC Biopharm (NASDAQ: TCBP) announced that the FDA granted orphan drug status to its lead product, OmnImmune®, for treating Acute Myeloid Leukemia (AML). This designation allows for a seven-year exclusive marketing period post-approval, enhancing commercial protection for OmnImmune®. The company aims to advance OmnImmune® through Phase 2b/3 trials, leveraging its innovative allogeneic gamma-delta T cell therapies. TC Biopharm positions itself at the forefront of cancer therapy development, with plans for enrollment in trials in both the UK and the US.
TC Biopharm (NASDAQ: TCBP) announced a significant enhancement of its intellectual property (IP) portfolio, which includes 6 granted patents and 45 pending applications related to gamma-delta T cell therapies. The IP covers revolutionary 'co-stimulatory' CAR-T cells aimed at lessening toxicity and expanding targeted therapy options. CEO Bryan Kobel emphasized the importance of this portfolio in establishing a competitive edge and advancing clinical development. The company continues to file additional applications, indicating a commitment to innovation in cancer and viral treatment therapies.
FAQ
What is the current stock price of TC BioPharm (Holdings) (TCBP)?
What is the market cap of TC BioPharm (Holdings) (TCBP)?
